Clearside Biomedical, Inc is a pioneering biotechnology company based in Alpharetta, GA, specializing in the development and delivery of innovative treatments for retinal diseases. Their groundbreaking technology allows for precise administration of therapeutic drugs to the back of the eye, targeting irreversible and debilitating ocular conditions. With a focus on preserving and improving vision, Clearside Biomedical is dedicated to making a difference in the lives of patients with serious back of the eye diseases.
Through their proprietary suprachoroidal space (SCS) delivery approach, Clearside Biomedical has developed XIPERE, the first FDA-approved product for suprachoroidal administration. This injectable suspension of triamcinolone acetonide is the first commercial therapy for macular edema associated with uveitis, providing unprecedented access to the posterior regions of the eye. With ongoing clinical trials and a robust pipeline, Clearside Biomedical continues to push the boundaries of retinal disease treatment and redefine the standard of care.
Generated from the website